bioRxivImmunologyPreprint
Previously unrecognized non-reproducible antibody-antigen interactions and their implications for diagnosis of viral infections including COVID-19
J. Pan, L. Yang, Y. Deng, B. Sun, L. Zhang, W. Wu, J. Li, H. Cheng, Y. Li, W. Xu, J. Yang, Y. Sun, H. Fei, Q. Xue, Y. Zhou, H. Wang, P. Zheng, H. Chen, F. C. Zhu, D. Peng, D. Gu, J. Han, J. Qiu, H. Ma
Abstract
Antibody-antigen (Ab-Ag) interactions are canonically described by a model which exclusively accommodates non-interaction (0) or reproducible-interaction (RI) states, yet this model is inadequate to explain often-encountered non-reproducible signals. Here, by monitoring diverse experimental systems and confirmed COVID-19 clinical sera using a peptide microarray, we observed that non-specific interactions (NSI) comprise a substantial proportion of non-reproducible antibody-based results. This enabled our discovery and capacity to reliably identify non-reproducible Ab-Ag interactions (NRI), as well as our development of a powerful explanatory model ("0-RI-NRI-Hook four-state model") that is [mAb]-dependent, regardless of specificity, which ultimately shows that both NSI and NRI are not predictable yet certain-to-happen. In experiments using seven FDA-approved mAb drugs, we demonstrated the use of NSI counts in predicting epitope type. Beyond challenging the centrality of Ab-Ag interaction specificity data in serology and immunology, our discoveries also facilitated the rapid development of a serological test with uniquely informative COVID-19 diagnosis performance.
- organism: human
- assay: proteomics
- research focus: host-pathogen & immune response
- research focus: dimensionality reduction
- approach: experimental assay
Reproducibility ledger
Nobody has reported trying to reproduce this paper yet. Did you replicate an experiment or run the code? Your report saves the next lab a week.
Sign in to file a reproducibility report.
Related papers
- Validation and Performance Comparison of Three SARS-CoV-2 Antibody Assays
S. Lu, K. J. Paiva, … E. Yakirevich·bioRxiv·May 29, 2020
- Antibodies targeting conserved non-canonical antigens and endemic coronaviruses associate with favorable outcomes in severe COVID-19
S. P. Peddireddy, S. A. Rahman, … J. Das·bioRxiv·Jan 24, 2022
- Glycan reactive anti-HIV-1 antibodies bind the SARS-CoV-2 spike protein but do not block viral entry
D. Mannar, K. Leopold, S. Subramaniam·bioRxiv·Jan 3, 2021
- Evidence for Deleterious Antigenic Imprinting in SARS-CoV-2 Immune Response
S. R. Sen, E. C. Sanders, … G. A. Weiss·bioRxiv·May 21, 2021
- Multivalent binding model quantifies antibody species from systems serology
Armaan A. Abraham, Zhixin Cyrillus Tan, … Aaron S. Meyer·bioRxiv·Jul 5, 2024
- Comparative analyses of SARS-CoV-2 binding (IgG, IgM, IgA) and neutralizing antibodies from human serum samples
L. Mazzini, D. Martinuzzi, … E. Montomoli·bioRxiv·Aug 10, 2020